Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 5, 2016, Pages

  Lip, Gregory Y H ^a   Wrigley, Benjamin J ^a   Pisters, Ron ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; HEART FAILURE; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM; SYSTEMATIC REVIEW; COMPLICATION; HUMAN; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOEMBOLISM;

ANTICOAGULANTS; HEART FAILURE; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOEMBOLISM;

EID: 84964988273     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003333.pub2     Document Type: Review

References (41)

1. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK. Efficacy of antithrombotic therapy in chronic heart failure: The HELAS study. The European Journal of Heart Failure 2006;8:428-432.
2. Cleland JG, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004;148:157-64.
3. Massie BM, Collins JF, Ammon SE, Armstrong PW. Cleland JGF, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR. Randomized trial of warfarin, aspirin and clopidogrel in patients with chronic heart failure. The warfarin and antiplatelet therapy in chronic heart failure (WATCH) trial. Circulation 2009;119:1616-1624.
4. Echemann M, Alla F, Briancon S, Juilliere Y, Virion JM, Mertes PM, Villemot JP, Zannad F, Aliot E, Breton Ch, KhalifE K, Neimann JL, Allam S, Admant P, Baille N, Bellanger P, D'Hotel R, Dambrine P, Dodet JF, Graille M, Kessler M, Rebeix G, Royer, Saulnier JP, Thisse JY, Trutt B, Vidal P, Vuillemin MCh, Delahaye, Ducimetiere P, Fagnani F, Guize L, EPICAL Investigators. Epidemiologie de l'Insuffisance Cardiaque Avancee en Lorraine. Echemann M, Alla F, Briancon S, Juilliere Y, Virion JM, Mertes PM, Villemot JP, Zannad F, Aliot E, Breton Ch, KhalifE K, Neimann JL, Allam S, Admant P, Baille N, Bellanger P, D'Hotel R, Dambrine P, Dodet JF, Graille M, Kessler M, Rebeix G, Royer, Saulnier JP, Thisse JY, Trutt B, Vidal P, Vuillemin MCh, Delahaye, Ducimetiere P, Fagnani F, Guize L, EPICAL Investigators. Epidemiologie de l'Insuffisance Cardiaque Avancee en Lorraine. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction severe heart failure and left ventricular systolic dysfunction (EPICAL study). Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study). Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study). Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study).. Eur J Heart Fail 2002;4(5):647-54.
5. Falk RH, Pollak A, Tandon PK, Packer M. The effect of warfarin on prevalence of stroke in patients with severe heart failure. JACC. 1993; Vol. 21 (suppl), issue 2:218A.
6. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye LA, Goldhaber SZ, Pfeffer MA. Ventricular dysfunction and the risk of stroke after myocardial infarction.. N Engl J Med 1997;336:251-7.
7. Dries DL, Domanski MJ, Waclawiw MA, Gersh BJ. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol 1997;79:909-913.
8. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolicdysfunction and sinus rhythm: evidence for gender differences in the studies ofleft ventricular dysfunction trials. Am Coll Cardiol 1997;29:1074-80.
9. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN, for the V-HeFT VA Cooperative Studies Group. Incidence of thromboembolic events in congestive heart failure. Circulation 1993;87 (Suppl VI):VI194-VI101.
10. Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000;54(2):288-94.
11. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of LeftVentricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998;31:419-25.
12. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
13. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - II:Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994;308:159-68.
14. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.. BMJ 2002;324(7329):71-86.
15. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atria fibrillation. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atria fibrillation. N Engl J Med 1990;323:1505-1511.
16. CAPRIE Steering Committee. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
17. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Tristani F, Harston WE, at al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552.
18. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
19. Faulkner G, Prichard P, Somerville K, Langman MJ. Aspirin and bleeding peptic ulcers in the elderly. BMJ 1988;297:1311-3.
20. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000 2000;355:1575-81.
21. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Bradenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525-31.
22. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis. Ann Intern Med. 1999;131:492-501.
23. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Reviewers' Handbook 5.1.0 (updated March 2011) The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org..
24. Klimt CR, Knatterud GL, Stamler J, Meier P. Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary preventionwith persantine and aspirin. J Am Coll Cardiol 1986;7:251-69.
25. Kyrle PA, Korninger C, Gossinger H, Glogar D, Lechner K, Niessner H, et al. Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardio-myopathy. Thromb Haemost 1985;54:521-523.
26. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for Studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org..
27. Li Saw Hee FL, Lip GYH. Atrial Fibrillation, Thromboembolism and Antithrombotic therapy. International Journal of Clinical Practice 1999;53:110-17.
28. Lip GYH. Intracardiac thrombus formation in cardiac impairment: Investigation and the Role of Anticoagulant Therapy. Postgraduate Medical Journal 1996;72:731-38.
29. Felmeden DC, Lip GY. Antithrombotic therapy in hypertension: a Cochrane Systematic review. J Hum Hypertens 2005;19:185-96.
30. Loh E, St. John Sutton M, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-257.
31. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardialinfarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II. Am J Cardiol 1997;79:115-9.
32. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effects of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
33. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175-8.
34. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New England Journal of Medicine 1992;327:685-691.
35. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine 1991;325:293-302.
36. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study; final results. Circulation 1991;84:527-39.
37. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691.
38. Stein PD, Dalen JE, Goldman S, Theroux P. Antithrombotic therapy in patients with saphenous vein and internal mammaryartery bypass grafts. Chest 1998;114(5 Suppl):658S-665S.
39. Swedberg K, for the CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandanavian Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
40. Sze PC, Reitman D, Pincus MM, Sacks HS, Chalmers TC. Antiplatelet agents in the secondary prevention of stroke: meta-analysis of therandomized control trials. Stroke 1988;19:436-42.
41. Turpie AG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993;329:524-9.